Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.

@article{Inoue2000TreatmentOH,
  title={Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.},
  author={Keji Inoue and Joel W. Slaton and Darren W. Davis and Daniel J. Hicklin and David James McConkey and Takashi Karashima and Robert R Radinsky and Colin P. N. Dinney},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2000},
  volume={6 7},
  pages={2635-43}
}
Vascular endothelial cell growth factor (VEGF) regulates angiogenesis and metastasis of bladder cancer (transitional cell carcinoma, TCC) through binding to VEGF receptor-2 (VEGFR-2). In this study, we evaluated whether the anti-VEGFR monoclonal antibody (Mab) DC101 in combination with paclitaxel inhibited tumorigenesis, angiogenesis, and metastasis of human TCC growing within the bladder of athymic nude mice. In vivo therapy with Mab DC101 and paclitaxel induced significant regression of… CONTINUE READING
51 Citations
83 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 83 references

Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma

  • V. Ravery, J. Jouanneau, +4 authors D. K. Chopin
  • Urol. Res.,20:
  • 1992
Highly Influential
10 Excerpts

Similar Papers

Loading similar papers…